Richard Glynne, Ph.D.

Venture Partner; President & CSO, Inception Therapeutics Discovery Engine, Versant Ventures

Dr. Richard Glynne is a venture partner at Versant as well as president and CSO of Versant’s Inception Therapeutics Discovery Engine. Richard joined Inception as CSO in 2018. Previously, he led search and evaluation for immune oncology, immunology and digital therapeutics in the business development group at Novartis. Prior to his BD role, Richard served as an executive director, leading a research group at the Genomics Institute of the Novartis Research Foundation that focused on infectious disease and immunology and contributed to multiple preclinical and clinical development programs. Richard trained in immunology and genetics during his Ph.D. (ICRF, London) and post-doc (HHMI, Stanford), after which he held leadership positions in Eos Biotechnology and Phenomix Corporation, before joining Novartis in 2004.